Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[11C]-GMOM
- Development stage
- Unknown
- Lead developer
- Vrije University Medical Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
[11C]-GMOM (full chemical name: [11C]N-(2-chloro-5-thiomethylphenyl)-N'-(3-methoxyphenyl)-N'-methylguanidine) is a carbon-11 radiolabeled small molecule PET radiotracer developed as a diagnostic imaging agent targeting the N-methyl-D-aspartate (NMDA) / phencyclidine (PCP) receptor ion channel in the brain. Developed by Vrije Universiteit Medisch Centrum (Amsterdam UMC), it is a methylguanidine derivative with high affinity (Ki ~ 5.2 nM) for the PCP binding site. The tracer is used to quantify NMDA receptor binding in vivo, providing a tool to study conditions involving glutamate neurotransmission dysregulation, such as schizophrenia, depression, and various neurological disorders. It has been evaluated in human dosimetry and biodistribution studies, demonstrating an effective dose profile suitable for serial PET scanning.
- Other names
- [11C]N-(2-chloro-5-thiomethylphenyl)-N'-(3-methoxyphenyl)-N'-methylguanidine
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on [11C]-GMOM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [11C]-GMOM.